Mark Zorbas
Overview
Explore the profile of Mark Zorbas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Evans M, Butt M, Belanger P, Cummings T, Gremminger J, Zorbas M
Auton Neurosci
. 2019 Mar;
218:51-53.
PMID: 30890348
Tanezumab, a humanized monoclonal anti-NGF antibody, has demonstrated efficacy and safety profiles in Phase III clinical trials of chronic pain. In a 24-week study in non-human primates, morphological observations of...
2.
Belanger P, Butler P, Butt M, Bhatt S, Foote S, Shelton D, et al.
Toxicol Sci
. 2017 May;
158(2):319-333.
PMID: 28525647
Tanezumab, a humanized monoclonal antibody against nerve growth factor is in development for treatment of chronic pain. Three nonclinical studies assessed effects of clinically relevant and supratherapeutic doses of tanezumab...
3.
Marcek J, Okerberg C, Liu C, Potter D, Butler P, Boucher M, et al.
J Chem Neuroanat
. 2016 May;
76(Pt B):133-141.
PMID: 27233661
Nerve growth factor (NGF) blocking therapies are an emerging and effective approach to pain management. However, concerns about the potential for adverse effects on the structure and function of the...
4.
Bowman C, Evans M, Cummings T, Oneda S, Butt M, Hurst S, et al.
Reprod Toxicol
. 2014 Dec;
53:105-18.
PMID: 25461901
Two intravenous studies with tanezumab, an anti-nerve growth factor monoclonal antibody, were conducted in pregnant cynomolgus monkeys to assess potential effects on pregnancy and pre- and postnatal development. Study 1...
5.
Butt M, Evans M, Bowman C, Cummings T, Oneda S, Shelton D, et al.
Toxicol Sci
. 2014 Oct;
142(2):463-76.
PMID: 25326242
Tanezumab, an antibody to nerve growth factor, was administered to pregnant cynomolgus monkeys at 0, 0.5, 4, and 30 mg/kg weekly, beginning gestation day (GD) 20 through parturition (∼GD165). Maternal...
6.
Zorbas M, Hurst S, Shelton D, Evans M, Finco D, Butt M
Regul Toxicol Pharmacol
. 2010 Dec;
59(2):334-42.
PMID: 21130822
Nerve growth factor (NGF) is an important mediator of pain and hyperalgesia and has become a target of novel analgesic therapeutics. Tanezumab is a humanized IgG(2) antibody that binds NGF...
7.
Burns-Naas L, Lee C, Evering W, Ahern L, Webber S, Zorbas M
J Immunotoxicol
. 2008 Oct;
2(3):123-39.
PMID: 18958666
Rupintrivir, also known as AG7088, is a small molecule 3C protease inhibitor designed to target human rhinovirus as a potential intranasal treatment for the common cold. The ability of rupintrivir...
8.
Burns-Naas L, White Jr K, McCay J, Ivett J, Webber S, Zorbas M
Hum Exp Toxicol
. 2005 Apr;
24(2):67-78.
PMID: 15850281
The objective of these investigations was to determine whether exposure to the HIV-1 protease inhibitor nelfinavir compromises immune function in Sprague Dawley rats. Animals (20/sex per group) were exposed orally...
9.
Burns-Naas L, Stump D, Webber S, Holson J, Masarjian L, Furman G, et al.
Regul Toxicol Pharmacol
. 2003 Nov;
38(3):304-16.
PMID: 14623481
The potential for nelfinavir mesylate (VIRACEPT) to produce reproductive toxicity was evaluated in rats administered oral doses of 200, 500, or 1000mg/kg/day. In the fertility and early embryonic development to...
10.
Burns-Naas L, Webber S, Stump D, Holson J, Masarjian L, Zorbas M
Regul Toxicol Pharmacol
. 2003 Nov;
38(3):291-303.
PMID: 14623480
The potential for nelfinavir mesylate (VIRACEPT) to induce maternal and embryo-fetal toxicity was evaluated in rats and rabbits following oral administration. The drug was administered by gavage to rats at...